See more : Pediatrix Medical Group, Inc. (MD) Income Statement Analysis – Financial Results
Complete financial analysis of XBiotech Inc. (XBIT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of XBiotech Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SCHMID Group N.V. Warrants (SHMDW) Income Statement Analysis – Financial Results
- WillScot Holdings Corporation (WSC) Income Statement Analysis – Financial Results
- Flame Acquisition Corp. (FLME) Income Statement Analysis – Financial Results
- Kagome Co., Ltd. (2811.T) Income Statement Analysis – Financial Results
- Motorcar Parts of America, Inc. (MPAA) Income Statement Analysis – Financial Results
XBiotech Inc. (XBIT)
About XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 4.01M | 18.39M | 44.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.74M | 651.00K | 5.82M | 34.55M | 2.36M | 2.43M | 1.48M | 698.00K | 699.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.74M | 3.36M | 12.57M | 9.45M | -2.36M | -2.43M | -1.48M | -698.00K | -699.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 83.77% | 68.36% | 21.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 32.85M | 31.54M | 28.27M | 9.53M | 24.09M | 15.73M | 26.42M | 42.49M | 31.31M | 14.33M | 7.94M | 13.33M |
| General & Administrative | 4.66M | 6.31M | 9.39M | 18.20M | 7.14M | 5.27M | 7.64M | 10.28M | 6.20M | 7.45M | 1.99M | 1.83M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.66M | 6.31M | 9.39M | 18.20M | 7.14M | 5.27M | 7.64M | 10.28M | 6.20M | 7.45M | 1.99M | 1.83M |
| Other Expenses | 0.00 | -121.00K | -132.00K | -503.00K | 750.01M | 4.00K | 0.00 | 0.00 | 21.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 37.51M | 37.85M | 37.66M | 27.73M | 31.23M | 20.99M | 34.06M | 52.76M | 37.51M | 21.78M | 9.93M | 15.16M |
| Cost & Expenses | 37.51M | 38.50M | 43.48M | 62.27M | 31.23M | 20.99M | 34.06M | 52.76M | 37.51M | 21.78M | 9.93M | 15.16M |
| Interest Income | 10.42M | 3.82M | 467.00K | 2.46M | 564.00K | 400.00K | 354.00K | 49.00K | 0.00 | 1.00K | 0.00 | 3.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.74M | 2.61M | 2.65M | 2.24M | 2.36M | 2.43M | 1.48M | 698.00K | 699.00K | 664.00K | 784.00K | 946.00K |
| EBITDA | -35.77M | -31.88M | -22.43M | -16.04M | -28.87M | -18.71M | -32.58M | -52.06M | -36.81M | -21.11M | -9.14M | -14.21M |
| EBITDA Ratio | 0.00% | -725.09% | -118.10% | -44.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -37.51M | -34.49M | -25.08M | -18.28M | -31.23M | -20.99M | -34.06M | -52.76M | -37.51M | -21.78M | -9.93M | -15.16M |
| Operating Income Ratio | 0.00% | -860.10% | -136.36% | -41.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 13.20M | 902.00K | -376.00K | 5.45M | 749.69M | -144.00K | 909.00K | 2.00K | 27.00K | 54.00K | -2.00K | 3.00K |
| Income Before Tax | -24.31M | -33.59M | -25.46M | -12.83M | 718.45M | -21.14M | -33.15M | -52.76M | -37.48M | -21.72M | -9.93M | -15.16M |
| Income Before Tax Ratio | 0.00% | -837.61% | -138.40% | -29.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 244.00K | -688.00K | -8.04M | -1.61M | 49.82M | -144.00K | -909.00K | -2.00K | -6.00K | -54.00K | 2.00K | 0.00 |
| Net Income | -24.56M | -32.90M | -17.41M | -11.22M | 668.63M | -21.14M | -33.15M | -52.76M | -37.48M | -21.72M | -9.93M | -15.16M |
| Net Income Ratio | 0.00% | -820.45% | -94.67% | -25.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.81 | -1.08 | -0.58 | -0.36 | 17.17 | -0.59 | -0.95 | -1.63 | -1.22 | -0.68 | -0.31 | -0.48 |
| EPS Diluted | -0.81 | -1.08 | -0.58 | -0.36 | 14.44 | -0.59 | -0.95 | -1.63 | -1.22 | -0.68 | -0.31 | -0.48 |
| Weighted Avg Shares Out | 30.32M | 30.44M | 30.04M | 30.82M | 38.95M | 35.80M | 34.88M | 32.40M | 30.80M | 31.72M | 31.72M | 31.72M |
| Weighted Avg Shares Out (Dil) | 30.44M | 30.44M | 30.04M | 30.82M | 46.32M | 35.80M | 34.88M | 32.40M | 30.80M | 31.72M | 31.72M | 31.72M |
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc.
NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP announces it has commenced an investigation of XBiotech Inc. (“XBiotech”) (NASDAQ:XBIT) concerning possible violations of federal securities laws. On April 20, 2017, XBiotech announced that the European Medicines Agency rendered a negative trend vote...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of XBiotech, Inc.
NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of XBiotech, Inc. (NASDAQGS:XBIT) (“XBiotech”) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors. On July 2, 2016, the European Society...
UPCOMING DEADLINE ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in XBiotech, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit
STEVENSON, Md.--(BUSINESS WIRE)--The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Texas on behalf of purchasers of XBiotech,...
SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of XBiotech Inc.
BALA CYNWYD, Pa.--(BUSINESS WIRE)--Law Office of Brodsky & Smith, LLC announces an investigation of XBiotech Inc. (“XBiotech” or the “Company”) (Nasdaq: XBIT) for potential violations of federal securities laws and breaches of the XBiotech Board’s fiduciary duties. Click here to...
The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of XBiotech, Inc. Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased XBiotech, Inc. (“XBiotech” or the “Company”) (Nasdaq: XBIT) securities between April 15, 2015 and November 23, 2015,...
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of XBiotech Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of February 1, 2016
NEW YORK--(BUSINESS WIRE)--The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of XBiotech Inc. (“XBiotech”) (Nasdaq:XBIT) between April 15, 2015 and November 23, 2015. You are hereby...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of XBiotech Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of February 1, 2016
NEW YORK--(BUSINESS WIRE)--The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of XBiotech Inc. (“XBiotech”) (Nasdaq: XBIT) between April 15, 2015 and November 23, 2015. You are...
XBIT INVESTOR ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving XBiotech Inc. and a Lead Plaintiff Deadline of February 1, 2016
NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Texas on behalf of investors who purchased XBiotech Inc. (Nasdaq:XBIT) securities between April 15, 2015...
DEADLINE REMINDER: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against XBiotech Inc. and Encourages Investors to Contact the Firm before the Deadline
IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against XBiotech Inc. (“XBiotech” or the “Company”) (Nasdaq: XBIT). Investors who purchased or otherwise acquired shares between April 15, 2015 and November 23,...
GPM Announces the Filing of a Securities Class Action on Behalf of XBiotech, Inc. Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces the filing of a class action lawsuit on behalf of investors of XBiotech, Inc. ("XBiotech" or the "Company") (Nasdaq: XBIT) who purchased shares between April 15, 2015 and November 23, 2015,...
Source: https://incomestatements.info
Category: Stock Reports